<DOC>
	<DOCNO>NCT01506336</DOCNO>
	<brief_summary>The objective compare efficacy safety masitinib 12 mg/kg/day sunitinib 50 mg/day treatment patient gastro-intestinal stromal tumor resistant imatinib .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Efficacy Safety Masitinib Comparison Sunitinib Patients With Gastro-Intestinal Stromal Tumour Resistant Imatinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Histological proven , metastatic , locally advance nonoperable GIST 2 . Measurable tumor lesion longest diameter ≥ 20 mm use conventional technique ≥ 10 mm spiral CT scan accord RECIST criterion 3 . Ckit ( CD117 ) positive tumor detect immunohistochemically document mutation ckit time available 4 . Patients resistant imatinib dose 400 mg/day 1 . Patient treat cancer GIST cancer within 5 year enrolment , exception basal cell carcinoma cervical cancer situ 2 . Patient active central nervous system ( CNS ) metastasis history CNS metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>GIST</keyword>
	<keyword>resistant</keyword>
	<keyword>imatinib</keyword>
	<keyword>gastro intestinal stromal tumor resistant imatinib</keyword>
</DOC>